Related references
Note: Only part of the references are listed.Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) A 26-week double-blind study
David Russell-Jones et al.
DIABETES CARE (2012)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
USE OF CONCOMITANT GLUCOSE-LOWERING THERAPIES AND ASSOCIATED TREATMENT RESULTS OBSERVED IN CLINICAL TRIALS OF TWICE-DAILY EXENATIDE
Richard Pencek et al.
ENDOCRINE PRACTICE (2012)
Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
Baptist Gallwitz et al.
LANCET (2012)
Death during Intensive Glycemic Therapy of Diabetes: Mechanisms and Implications
Philip E. Cryer
AMERICAN JOURNAL OF MEDICINE (2011)
Serious Cardiovascular Outcomes in Diabetes The Role of Hypoglycemia
Natalia Yakubovich et al.
CIRCULATION (2011)
GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials
K. Esposito et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists A review of their efficacy and tolerability
Alan J. Garber
DIABETES CARE (2011)
Evidence Linking Hypoglycemic Events to an Increased Risk of Acute Cardiovascular Events in Patients With Type 2 Diabetes
Stephen S. Johnston et al.
DIABETES CARE (2011)
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
A. Garber et al.
DIABETES OBESITY & METABOLISM (2011)
Self-reported experience of hypoglycemia among adults with type 2 diabetes mellitus (Exhype)
Billie Pettersson et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2011)
DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
Thomas Blevins et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells
Colin A. Leech et al.
PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY (2011)
Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes
Caroline M. Apovian et al.
AMERICAN JOURNAL OF MEDICINE (2010)
A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin
J. Liutkus et al.
DIABETES OBESITY & METABOLISM (2010)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Michaela Diamant et al.
LANCET (2010)
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
Richard M. Bergenstal et al.
LANCET (2010)
Exenatide is Non-inferior to Insulin in Reducing HbA1c : An Integrated Analysis of 1423 Patients with Type 2 Diabetes
Thomas Blevins et al.
POSTGRADUATE MEDICINE (2010)
GLUT2 mutations, translocation, and receptor function in diet sugar managing
Armelle Leturque et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
Suppression of Sulfonylurea- and Glucose-Induced Insulin Secretion In Vitro and In Vivo in Mice Lacking the Chloride Transport Protein ClC-3
Dai-Qing Li et al.
CELL METABOLISM (2009)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
Michael Nauck et al.
DIABETES CARE (2009)
Roles of cAMP signalling in insulin granule exocytosis
S. Seino et al.
DIABETES OBESITY & METABOLISM (2009)
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
D. Russell-Jones et al.
DIABETOLOGIA (2009)
Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes
Takashi Kadowaki et al.
ENDOCRINE JOURNAL (2009)
Enhanced Rap1 Activation and Insulin Secretagogue Properties of an Acetoxymethyl Ester of an Epac-selective Cyclic AMP Analog in Rat INS-1 Cells STUDIES WITH 8-pCPT-2′-O-Me-cAMP-AM
Oleg G. Chepurny et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Mechanisms of biphasic insulin-granule exocytosis - roles of the cytoskeleton, small GTPases and SNARE proteins
Zhanxiang Wang et al.
JOURNAL OF CELL SCIENCE (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Glucose-dependent potentiation of mouse islet insulin secretion by Epac activator 8-pCPT-2′-O-Me-cAMP-AM
Grant G. Kelley et al.
ISLETS (2009)
Glucose-induced cyclic AMP oscillations regulate pulsatile insulin secretion
Oleg Dyachok et al.
CELL METABOLISM (2008)
Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
Thomas J. Moretto et al.
CLINICAL THERAPEUTICS (2008)
Glucose and GLP-1 stimulate cAMP production via distinct adenylyl cyclases in INS-1E insulinoma cells
Lavoisier S. Ramos et al.
JOURNAL OF GENERAL PHYSIOLOGY (2008)
Role of the cAMP sensor Epac as a determinant of KATP channel ATP sensitivity in human pancreatic β-cells and rat INS-1 cells
Guoxin Kang et al.
JOURNAL OF PHYSIOLOGY-LONDON (2008)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
Wook Kim et al.
PHARMACOLOGICAL REVIEWS (2008)
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Helle Linnebjerg et al.
REGULATORY PEPTIDES (2008)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1
Jocelyn de Heer et al.
DIABETES (2007)
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
Tina Vilsboll et al.
DIABETES CARE (2007)
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Maire E. Doyle et al.
PHARMACOLOGY & THERAPEUTICS (2007)
Cyclic AMP/cAMP-GEF pathway amplifies insulin exocytosis induced by Ca2+ and ATP in rat islet beta-cells
H Hashiguchi et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2006)
A cAMP and Ca2+ coincidence detector in support of Ca2+-induced Ca2+ release in mouse pancreatic β cells
GX Kang et al.
JOURNAL OF PHYSIOLOGY-LONDON (2005)
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
RA DeFronzo et al.
DIABETES CARE (2005)
Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia
KB Degn et al.
DIABETES (2004)
Stimulation of insulin release by glucose in associated with an increase in the number of docked granules in the β-cells of rat pancreatic islets
SG Straub et al.
DIABETES (2004)
Glucagon-like peptide-1: Regulation of insulin secretion and therapeutic potential
J Gromada et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2004)
Glucose-induced translational control of proinsulin biosynthesis is proportional to preproinsulin mRNA levels in islet β-cells but not regulated via a positive feedback of secreted insulin
B Wicksteed et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Insulin granule dynamics in pancreatic beta cells
P Rorsman et al.
DIABETOLOGIA (2003)
Voltage-dependent K+ channels in pancreatic beta cells:: Role, regulation and potential as therapeutic targets
PE MacDonald et al.
DIABETOLOGIA (2003)
Ca2+-induced Ca2+ release in the pancreatic β-cell:: Direct evidence of endoplasmic reticulum Ca2+ release
TK Graves et al.
ENDOCRINOLOGY (2003)
SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic B-cells
L Eliasson et al.
JOURNAL OF GENERAL PHYSIOLOGY (2003)
Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 β-cells
T Tsuboi et al.
BIOCHEMICAL JOURNAL (2003)
Amplification of exocytosis by Ca (2+)-induced Ca2+ release in INS-1 pancreatic beta cells
GX Kang et al.
JOURNAL OF PHYSIOLOGY-LONDON (2003)
The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion
PE MacDonald et al.
DIABETES (2002)
Glucagon-like peptide-1 receptor activation antagonizes voltage-dependent repolarizing K+ currents in β-cells -: A possible glucose-dependent insulinotropic mechanism
PE MacDonald et al.
DIABETES (2002)
Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism
PE Light et al.
MOLECULAR ENDOCRINOLOGY (2002)
Synergistic effect of dimethyl sulfoxide on glucagon-like peptide 1 (GLP-1)-stimulated insulin secretion and gene transcription in INS-1 cells: characterization and implications
DM Kemp et al.
BIOCHEMICAL PHARMACOLOGY (2002)
The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects
HX Hui et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002)
Triggering and augmentation mechanisms, granule pools, and biphasic insulin secretion
TK Bratanova-Tochkova et al.
DIABETES (2002)
A subset of 50 secretory granules in close contact with L-type Ca2+ channels accounts for first-phase insulin secretion in mouse β-cells
S Barg et al.
DIABETES (2002)
The insulinotropic effect of acute exendin-4 administered to humans: Comparison of nondiabetic state to type 2 diabetes
JM Egan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic β-cells
GX Kang et al.
JOURNAL OF PHYSIOLOGY-LONDON (2001)
Members of the Kv1 and Kv2 voltage-dependent K+ channel families regulate insulin secretion
PE MacDonald et al.
MOLECULAR ENDOCRINOLOGY (2001)
Regulation of the type III InsP3 receptor and its role in β cell function
RE Hagar et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2000)
Sustained expression of exendin-4 does not perturb glucose homeostasis, β-cell mass, or food intake in metallothionein-preproexendin transgenic mice
L Baggio et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
cAMP-GEFII is a direct target of cAMP in regulated exocytosis
N Ozaki et al.
NATURE CELL BIOLOGY (2000)
Ca2+ and electrolyte mobilization following agonist application to the pancreatic β cell line HIT
I Nakagaki et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2000)
KATP channels gated by intracellular nucleotides and phospholipids
T Baukrowitz et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2000)
Share Paper
